ZA200902940B - Substituted pyrazole and triazole compounds as KSP inhibitors - Google Patents

Substituted pyrazole and triazole compounds as KSP inhibitors

Info

Publication number
ZA200902940B
ZA200902940B ZA200902940A ZA200902940A ZA200902940B ZA 200902940 B ZA200902940 B ZA 200902940B ZA 200902940 A ZA200902940 A ZA 200902940A ZA 200902940 A ZA200902940 A ZA 200902940A ZA 200902940 B ZA200902940 B ZA 200902940B
Authority
ZA
South Africa
Prior art keywords
triazole compounds
substituted pyrazole
ksp inhibitors
ksp
inhibitors
Prior art date
Application number
ZA200902940A
Other languages
English (en)
Inventor
Yi Xia
Kris G Mendenhall
Paul A Barsanti
Annette O Walter
David Duhl
Paul A Renhowe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200902940B publication Critical patent/ZA200902940B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200902940A 2006-11-13 2009-04-29 Substituted pyrazole and triazole compounds as KSP inhibitors ZA200902940B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85896406P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
ZA200902940B true ZA200902940B (en) 2010-05-26

Family

ID=39144618

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902940A ZA200902940B (en) 2006-11-13 2009-04-29 Substituted pyrazole and triazole compounds as KSP inhibitors

Country Status (32)

Country Link
US (2) US8129358B2 (fr)
EP (1) EP2091926B1 (fr)
JP (1) JP5264755B2 (fr)
KR (1) KR20090081020A (fr)
CN (1) CN101558049B (fr)
AR (1) AR063805A1 (fr)
AU (1) AU2007323998B2 (fr)
BR (1) BRPI0719002A2 (fr)
CA (1) CA2668661A1 (fr)
CL (1) CL2007003272A1 (fr)
CO (1) CO6382171A2 (fr)
CR (1) CR10787A (fr)
DO (1) DOP2009000106A (fr)
EA (1) EA017748B1 (fr)
EC (1) ECSP099326A (fr)
ES (1) ES2557478T3 (fr)
GE (1) GEP20125389B (fr)
GT (1) GT200900122A (fr)
HN (1) HN2009000968A (fr)
IL (1) IL198471A0 (fr)
MA (1) MA30959B1 (fr)
MX (1) MX2009005071A (fr)
NI (1) NI200900084A (fr)
NO (1) NO20092226L (fr)
NZ (1) NZ576640A (fr)
PE (1) PE20081169A1 (fr)
SM (1) SMP200900045B (fr)
TN (1) TN2009000178A1 (fr)
TW (1) TW200831480A (fr)
UA (1) UA97256C2 (fr)
WO (1) WO2008063912A1 (fr)
ZA (1) ZA200902940B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
BRPI0806264A2 (pt) * 2007-01-05 2011-08-30 Novartis Ag derivados ciclizados como inibidores de eg-5
MX2012011910A (es) * 2010-04-15 2012-11-29 Novartis Ag Compuestos de triazol como inhibidores de ksp.
EP2558452A2 (fr) * 2010-04-15 2013-02-20 Novartis AG Composés d'oxazole et de thiazole comme inhibiteurs de ksp
US9663490B2 (en) * 2012-12-05 2017-05-30 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
CN105451773A (zh) * 2013-03-15 2016-03-30 诺华股份有限公司 细胞增殖抑制剂及其缀合物
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
MX367369B (es) 2013-12-04 2019-08-16 Merck Sharp & Dohme Proceso para preparar inhibidores de la transcriptasa inversa.
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
US20190161499A1 (en) * 2015-12-11 2019-05-30 Syngenta Participations Ag Pesticidally active 1,2,4-triazole derivatives
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5011472A (en) * 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5185450A (en) * 1991-02-19 1993-02-09 University Of South Florida Tetrazolium compounds for cell viability assays
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
AU4055400A (en) 1999-04-02 2000-10-23 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
EP1226129B1 (fr) 1999-10-27 2006-05-24 Cytokinetics, Inc. Procedes et compositions utilisant des quinazolinones
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
KR20030060904A (ko) 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
WO2002057244A1 (fr) 2001-01-19 2002-07-25 Cytokinetics, Inc. Inhibiteurs de la kinesine a base de phenothiazine
WO2002056880A1 (fr) 2001-01-19 2002-07-25 Cytokinetics, Inc. Inhibiteurs triphenylmethane de la kinesine
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
TW200300078A (en) 2001-11-08 2003-05-16 Univ Chicago Method of treating disorder related to high cholesterol concentration
WO2003043995A1 (fr) 2001-11-20 2003-05-30 Cytokinetics, Inc. Procede de racemisation de quinazolinones chirales
AU2002357053B2 (en) 2001-12-06 2008-05-15 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
AU2002364128B2 (en) 2001-12-06 2008-03-06 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
ATE447577T1 (de) 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
WO2003049527A2 (fr) 2001-12-06 2003-06-19 Merck & Co., Inc. Inhibiteurs miotitiques de la kinesine
AU2002357114B2 (en) * 2001-12-07 2008-07-24 Virginia Commonwealth University Treatment of neoplasia
CA2472470A1 (fr) 2002-01-10 2003-07-24 Neurogen Corporation Ligands recepteurs de l'hormone de concentration de la melanine: analogues de benzoimidazole substitue
CA2475879A1 (fr) 2002-02-15 2003-08-28 Cytokinetics, Inc. Synthesis de quinazolinones
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
WO2003103575A2 (fr) 2002-05-23 2003-12-18 Cytokinetics, Inc. Composes, compositions et procedes
CA2483627A1 (fr) 2002-05-23 2003-12-04 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
CN100421665C (zh) 2002-06-14 2008-10-01 麦克公司 有丝分裂驱动蛋白抑制剂
EP1515949B1 (fr) 2002-06-14 2007-03-14 Merck & Co., Inc. Inhibiteurs de kinesine mitotique
GB0214139D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US20060134767A1 (en) 2002-07-08 2006-06-22 Buser-Doepner Carolyn A Mitotic kinesin binding site
AU2003252025A1 (en) 2002-07-17 2004-02-02 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (fr) 2002-07-23 2008-04-16 Cytokinetics Inc Composes, compositions et procedes
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
EP1620092A4 (fr) 2003-05-07 2008-04-16 Cytokinetics Inc Composes, compositions et methodes
JP2007500746A (ja) 2003-05-15 2007-01-18 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
ES2318478T3 (es) * 2004-04-06 2009-05-01 Novartis Vaccines And Diagnostics, Inc. Inhibidores de quinesina mitotica.
CA2564215A1 (fr) * 2004-05-21 2005-12-01 Chiron Corporation Derives de quinolinone substituee en tant qu'inhibiteurs de kinesine mitotique
CA2571002A1 (fr) * 2004-06-18 2006-01-05 Chiron Corporation Derives de n-(1-(1-benzyl-4-phenyl-1h-imidazol-2-yl)-2,2-dymethylpropyl) benzamide et composes associes comme inhibiteurs de la proteine kinesine fuseau (ksp) pour le traitement du cancer
RU2007118523A (ru) * 2004-10-19 2008-11-27 Новартис Вэксинс Энд Диагностикс Инк. (Us) Производные индола и бензимидазола
US7829589B2 (en) * 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
MY147188A (en) * 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.

Also Published As

Publication number Publication date
AU2007323998B2 (en) 2011-09-22
US20100034813A1 (en) 2010-02-11
NO20092226L (no) 2009-08-12
NZ576640A (en) 2011-10-28
KR20090081020A (ko) 2009-07-27
ECSP099326A (es) 2009-06-30
GEP20125389B (en) 2012-01-25
SMAP200900045A (it) 2009-07-14
CA2668661A1 (fr) 2008-05-29
JP2010509365A (ja) 2010-03-25
ES2557478T3 (es) 2016-01-26
US20080200462A1 (en) 2008-08-21
MX2009005071A (es) 2009-05-25
JP5264755B2 (ja) 2013-08-14
EA017748B1 (ru) 2013-02-28
PE20081169A1 (es) 2008-09-24
CL2007003272A1 (es) 2008-03-24
TN2009000178A1 (en) 2010-10-18
NI200900084A (es) 2010-01-29
EA200900631A1 (ru) 2009-12-30
EP2091926A1 (fr) 2009-08-26
GT200900122A (es) 2011-09-14
US7902240B2 (en) 2011-03-08
TW200831480A (en) 2008-08-01
US8129358B2 (en) 2012-03-06
CN101558049B (zh) 2012-08-15
UA97256C2 (ru) 2012-01-25
CN101558049A (zh) 2009-10-14
AR063805A1 (es) 2009-02-18
IL198471A0 (en) 2010-02-17
CO6382171A2 (es) 2012-02-15
HN2009000968A (es) 2011-10-25
MA30959B1 (fr) 2009-12-01
BRPI0719002A2 (pt) 2013-12-17
SMP200900045B (it) 2010-03-01
AU2007323998A1 (en) 2008-05-29
CR10787A (es) 2009-07-02
WO2008063912A1 (fr) 2008-05-29
DOP2009000106A (es) 2009-05-31
EP2091926B1 (fr) 2015-10-21

Similar Documents

Publication Publication Date Title
IL198471A0 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
AP2010005167A0 (en) Pyrazole compounds and their use as RAF inhibitors
EP2222674B8 (fr) Amino triazoles en tant qu'inhibiteurs pi3k
IL193482A0 (en) Hydantoin based kinase inhibitors
HK1136820A1 (en) Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
HK1130780A1 (en) Pyrazoles as 11-beta-hsd-1
IL195278A0 (en) Triazole derivatives ii
IL193587A0 (en) Heterobicyclic pyrazole compounds and methods of use
EP2166849A4 (fr) Composés pyrazole substitués
HK1111995A1 (en) Substituted imidazole compounds as ksp inhibitors
PL2383271T3 (pl) Aminochinolony jako inhibitory GSK-3
EP2084139A4 (fr) Composés d'oxazolidinium et utilisation en tant qu'inhibiteurs d'hydrate
GB0622084D0 (en) Inhibitors of HSP90
HK1131128A1 (en) Triazole derivative
EP2084135A4 (fr) Pyrazoles
ZA200904029B (en) Triazole formulation
IL195331A0 (en) Hsp90 inhibitor
EP2341776A4 (fr) Composés, compositions et procédés comprenant des dérivés d'imidazole et de triazole
ZA200900625B (en) Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds
EP2015638A4 (fr) Dérivés d'imidazole substitués par triaryle et leurs utilisations dans l'inhibition du goût
ZA200808598B (en) Pyrrolopyrimidine derivatives used as HSP90 inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors